---
figid: PMC4505740__nihms655432f1
figlink: /pmc/articles/PMC4505740/figure/F1/
number: F1
caption: Molecular targeting of the mitogen-activated protein kinase (MAPK), PI3K,
  and CDK4 pathways and the associated mutation rates of potential molecular targets
  in advanced melanoma (). Activation of a receptor tyrosine kinase such as c-KIT
  results in the propagation of signal via the MAPK pathway leading to activation
  of RAS, RAF, MEK and ERK. This ultimately results in the gene expression and promotes
  cellular proliferation and survival. Mutated BRAF bypasses this ordered pathway
  and stimulates constitutive signaling, making it a prime target for vemurafenib
  and dabrafenib. Trametinib targets the downstream effector molecule MEK. Dysregulation
  of the PI3K pathway promotes melanoma progression. Small molecule inhibitors of
  the PI3K pathway are being clinically tested in combination with MAPK pathway inhibition.
  Similarly, CDK4 is an attractive candidate molecule to target in melanoma and is
  the focus of multiple clinical trials. Red=activated; gray=inactivated; green=normal
  function. Drugs (shown in boxes) that have been approved (bold), or in trial (non-bold,
  italics), are indicated.
pmcid: PMC4505740
papertitle: 'Targeted therapies in melanoma: Translational research at its finest.'
reftext: Allen W. Ho, et al. J Invest Dermatol. 2015 Aug;135(8):1929-1933.
pmc_ranked_result_index: '82172'
pathway_score: 0.9614046
filename: nihms655432f1.jpg
figtitle: Molecular targeting of the mitogen-activated protein kinase (MAPK), PI3K,
  and CDK4 pathways and the associated mutation rates of potential molecular targets
  in advanced melanoma ()
year: '2015'
organisms: Homo sapiens
ndex: 5c61dc93-dedc-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4505740__nihms655432f1.html
  '@type': Dataset
  description: Molecular targeting of the mitogen-activated protein kinase (MAPK),
    PI3K, and CDK4 pathways and the associated mutation rates of potential molecular
    targets in advanced melanoma (). Activation of a receptor tyrosine kinase such
    as c-KIT results in the propagation of signal via the MAPK pathway leading to
    activation of RAS, RAF, MEK and ERK. This ultimately results in the gene expression
    and promotes cellular proliferation and survival. Mutated BRAF bypasses this ordered
    pathway and stimulates constitutive signaling, making it a prime target for vemurafenib
    and dabrafenib. Trametinib targets the downstream effector molecule MEK. Dysregulation
    of the PI3K pathway promotes melanoma progression. Small molecule inhibitors of
    the PI3K pathway are being clinically tested in combination with MAPK pathway
    inhibition. Similarly, CDK4 is an attractive candidate molecule to target in melanoma
    and is the focus of multiple clinical trials. Red=activated; gray=inactivated;
    green=normal function. Drugs (shown in boxes) that have been approved (bold),
    or in trial (non-bold, italics), are indicated.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CDKN2A
  - BCL2
  - E2F7
  - CDK4
  - E2F2
  - FOSL1
  - TP53
  - BAD
  - E2F3
  - GNA11
  - GNAQ
  - E2F1
  - FOS
  - PIK3CD
  - E2F4
  - FOSL2
  - PIK3CB
  - NRAS
  - PLCB1
  - PLCE1
  - PLCB2
  - PLCB3
  - BRAF
  - PLCD1
  - PLCG1
  - PLCD4
  - PLCZ1
  - PTEN
  - E2F5
  - E2F6
  - JUND
  - ERBB4
  - MAPK1
  - MAPK3
  - PIK3R6
  - PIK3R5
  - PIK3R4
  - MDM2
  - JUN
  - KIT
  - MAP2K2
  - MAP2K1
  - NF1
  - JUNB
  - PLCD3
  - PIK3CA
  - PLXNA3
  - AKT3
  - PLCB4
  - FOSB
  - RAF1
  - PLCG2
  - ARAF
  - E2F8
  - PIK3R3
  - PIK3CG
  - PD-325901
  - Selumetinib
  - BEZ235
  - RO4987655
  - Trametinib
  - Dabrafenib
  - Cobimetinib
  - Binimetinib
  - Cancer
  - Lung cancer
  - Melanoma
genes:
- word: ARF
  symbol: ARF
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: BCL2
  symbol: BCL2
  source: hgnc_symbol
  hgnc_symbol: BCL2
  entrez: '596'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F7
  entrez: '144455'
- word: CDK4
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F2
  entrez: '1870'
- word: CDKN2A
  symbol: CDKN2A
  source: hgnc_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: AP1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOSL1
  entrez: '8061'
- word: p53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: BAD
  symbol: BAD
  source: hgnc_symbol
  hgnc_symbol: BAD
  entrez: '572'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F3
  entrez: '1871'
- word: GNA11
  symbol: GNA11
  source: hgnc_symbol
  hgnc_symbol: GNA11
  entrez: '2767'
- word: GNAQ
  symbol: GNAQ
  source: hgnc_symbol
  hgnc_symbol: GNAQ
  entrez: '2776'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
- word: FOS
  symbol: FOS
  source: hgnc_symbol
  hgnc_symbol: FOS
  entrez: '2353'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F4
  entrez: '1874'
- word: AP1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOSL2
  entrez: '2355'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: NRAS
  symbol: NRAS
  source: hgnc_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: p16
  symbol: p16
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB1
  entrez: '23236'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCE1
  entrez: '51196'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB2
  entrez: '5330'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB3
  entrez: '5331'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD1
  entrez: '5333'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCG1
  entrez: '5335'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD4
  entrez: '84812'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCZ1
  entrez: '89869'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F5
  entrez: '1875'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F6
  entrez: '1876'
- word: AP1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: JUND
  entrez: '3727'
- word: ERBB4
  symbol: ERBB4
  source: hgnc_symbol
  hgnc_symbol: ERBB4
  entrez: '2066'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: HDM2
  symbol: HDM2
  source: hgnc_alias_symbol
  hgnc_symbol: MDM2
  entrez: '4193'
- word: JUN
  symbol: JUN
  source: hgnc_symbol
  hgnc_symbol: JUN
  entrez: '3725'
- word: KIT
  symbol: KIT
  source: hgnc_symbol
  hgnc_symbol: KIT
  entrez: '3815'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: NF1
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: AP1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: JUNB
  entrez: '3726'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD3
  entrez: '113026'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: 63%
  symbol: '6.3'
  source: hgnc_alias_symbol
  hgnc_symbol: PLXNA3
  entrez: '55558'
- word: AKT3
  symbol: AKT3
  source: hgnc_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB4
  entrez: '5332'
- word: AP1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOSB
  entrez: '2354'
- word: AP1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: JUN
  entrez: '3725'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: AP1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOS
  entrez: '2353'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCG2
  entrez: '5336'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F8
  entrez: '79733'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
chemicals:
- word: PD-325901
  source: MESH
  identifier: C506614
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: BEZ235
  source: MESH
  identifier: C531198
- word: RO4987655
  source: MESH
  identifier: C559138
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Cobimetinib
  source: MESH
  identifier: C574276
- word: Binimetinib
  source: MESH
  identifier: C581313
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Melanoma
  source: ''
  identifier: ''
figid_alias: PMC4505740__F1
redirect_from: /figures/PMC4505740__F1
figtype: Figure
---
